cbt-101
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2017 (NCT03175224)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Brain Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Colonic Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Glioblastoma · Phase 1
- Kidney Neoplasms · Phase 1
- Lung Neoplasms · Phase 1
- Mutation · Phase 1
- Neoplasms · Phase 1
- Oncogene Protein tpr-met · Phase 1
- Oncogenes · Phase 1
- Pancreatic Neoplasms · Phase 1
- Proto-Oncogene Proteins c-met · Phase 1
- Stomach Neoplasms · Phase 1
- Thyroid Neoplasms · Phase 1
Mechanism of action
- cytokine-induced killer cellsSupplementation
cytokine-induced killer cells supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cbt-101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03175224 | Phase 1 | Jun 1, 2017 | Apollomics, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Apollomics, Inc. | For profit | 1 | 1 | 1 | 2017 |
1 organizations
Page 1 / 1